山东未名生物医药股份有限公司收到参股公司分红 1.35亿元
公告要点
- 分红事项：山东未名生物医药股份有限公司（*ST未名）近日收到参股公司北京科兴生物制品有限公司（北京科兴）分红款项人民币134,550,000元。
- 分红依据：此次分红根据北京科兴股东会决议，依据各股东在注册资本中的出资比例，对截至2025年12月31日累计可分配利润中的部分利润进行分配。
- 持股比例：山东未名生物医药股份有限公司持有北京科兴26.91%股权。
- 会计处理：公司对参股公司的长期股权投资采用权益法核算。本次分红将有助于改善公司的现金流，但对公司合并报表净利润无影响。
- 分红到账：截至公告日，山东未名生物医药已收到全部现金分红款项。
- 后续披露：公司将根据后续进展情况及时履行信息披露义务，提醒投资者关注投资风险。
对投资者的影响及需关注事项
- 现金流改善：本次1.35亿元的分红款到账，将显著增强公司现金流，有助于公司资金链的稳健运作，提升公司短期偿债和经营能力。
- 净利润不受影响：虽然分红有助于现金流，但由于采用权益法核算，对公司合并报表净利润无影响。投资者应关注现金流改善对公司经营状况的积极作用，但不应期待本次分红直接提升公司业绩收益。
- 股价潜在驱动：大额分红到账对公司资产和流动性构成利好，可能提升市场对公司财务健康状况的信心，从而对公司股价形成正面影响，尤其是在当前*ST状态下，这一现金流入具有积极意义。
- 风险提示：公司特别提醒广大投资者关注投资风险，密切关注后续信息披露。
事件详细背景
根据公告，北京科兴生物制品有限公司依据2025年12月31日累计可分配利润中的部分利润，向各股东按出资比例分红。山东未名生物医药持有北京科兴26.91%股权，本次获得现金分红1.3455亿元。截止公告披露日，已全部到账。
由于公司对北京科兴的投资采用权益法核算，本次分红仅改善现金流，不影响合并报表净利润。公司承诺将依规及时披露后续相关信息。
结论
综上，本次收到参股公司北京科兴1.35亿元分红，是公司近期现金流的重要补充，对资金状况改善具有实质意义。投资者应关注公司持续信息披露和后续财务表现。
免责声明：本文仅供投资参考，不构成任何投资建议。投资者请结合自身实际判断和风险承受能力，审慎决策。公司业绩及市场表现受多重因素影响，本文不承担由此产生的任何责任。
English Version
ST Weiming Receives RMB 135 Million Dividend from Sinovac Beijing
Key Highlights
- Dividend Received: Shandong Weiming Bio-Pharmaceutical Co., Ltd. (*ST Weiming) has recently received RMB 134,550,000 as dividend from its associate, Beijing Sinovac Biotech Co., Ltd. (Sinovac Beijing).
- Basis for Dividend: The dividend was distributed according to the Sinovac Beijing shareholder resolution, based on the registered capital proportion of each shareholder, distributing part of the accumulated distributable profits as of December 31, 2025.
- Equity Holding: ST Weiming holds a 26.91% stake in Sinovac Beijing.
- Accounting Method: The company accounts for its long-term equity investment in Sinovac Beijing using the equity method. The dividend will improve the company’s cash flow but will not impact consolidated net profit.
- Funds Received: As of the announcement date, ST Weiming has received the full dividend amount in cash.
- Disclosure Commitment: The company will promptly disclose further developments and reminds investors of investment risks.
Investor Impact and Price-sensitive Information
- Cash Flow Enhancement: The RMB 135 million cash inflow will significantly strengthen ST Weiming’s cash position, improve financial stability, and enhance short-term debt-servicing and operational capabilities.
- No Impact on Net Profit: As the company uses the equity method, the dividend will not boost consolidated net profit. Investors should note the positive impact on cash flow rather than expecting immediate profit growth from this dividend.
- Potential Share Price Catalyst: The substantial dividend receipt is a positive signal for the company’s assets and liquidity, which may boost market confidence and potentially support the share price, especially given the company’s current *ST (special treatment) status, where cash inflow is of heightened importance.
- Risk Warning: The company emphasizes attention to investment risks and the importance of following further disclosures.
Background Details
According to the announcement, Sinovac Beijing distributed part of its accumulated profits as of December 31, 2025, to shareholders in proportion to their capital contributions. ST Weiming, holding a 26.91% stake, received RMB 134.55 million, and all funds have been received as of the publication date.
As the equity method is used, the dividend improves cash flow but does not affect consolidated net profit. The company will disclose further relevant information as required.
Conclusion
In summary, this RMB 135 million dividend from Sinovac Beijing is a significant boost to ST Weiming’s cash flow and financial health. Investors should monitor further disclosures and ongoing financial performance.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should make prudent decisions based on their own circumstances and risk tolerance. Company performance and market trends are subject to multiple factors, and the author assumes no responsibility for any resulting losses.
